70459-04-0

Basic information

• Product Name: Norfloxacin EP Impurity G
• Synonyms: Norfloxacin EP Impurity G
• CAS NO: 70459-04-0
• Molecular Formula: C₁₇H₁₈FN₃O₄
• Molecular Weight: 347.3409232
• Product Categories: impurity
• Mol File: 70459-04-0.mol

Chemical Properties

• Melting Point: 292-293 °C(Solv: methanol (67-56-1))
• Boiling Point: 622.1°C at 760 mmHg
• Flash Point: 330°C
• Appearance: /
• Density: 1.453g/cm³
• Vapor Pressure: 2.46E-16mmHg at 25°C
• Refractive Index: 1.653
• PKA: 0.16±0.20(Predicted)
• CAS DataBase Reference: Norfloxacin EP Impurity G(CAS DataBase Reference)
• NIST Chemistry Reference: Norfloxacin EP Impurity G(70459-04-0)
• EPA Substance Registry System: Norfloxacin EP Impurity G(70459-04-0)

Safety Data

• Hazardous Substances Data: 70459-04-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Norfloxacin EP Impurity G is used as a reference compound for the identification, quality control, and purity assessment of Norfloxacin. Its presence in the final product is crucial for ensuring the safety, efficacy, and regulatory compliance of the drug.
Used in Research and Development:
Norfloxacin EP Impurity G serves as an essential tool in the research and development of new fluorinated quinolone antibacterials. It aids in understanding the structure-activity relationship, optimization of drug design, and evaluation of potential side effects or toxicities associated with the parent compound, Norfloxacin.
Used in Quality Control Laboratories:
Norfloxacin EP Impurity G is utilized as a reference material in quality control laboratories to validate analytical methods, such as high-performance liquid chromatography (HPLC) and other chromatographic techniques. This ensures the accuracy and reliability of the tests performed on Norfloxacin-containing products.
Used in Regulatory Compliance:
Norfloxacin EP Impurity G is employed in the development and validation of regulatory standards for Norfloxacin. It helps in establishing acceptable limits for impurities in the final drug product, ensuring that the medication meets the required safety and efficacy criteria set by regulatory authorities.

InChI:InChI=1/C17H18FN3O4/c1-2-20-9-12(17(24)25)16(23)11-7-13(18)15(8-14(11)20)21-5-3-19(10-22)4-6-21/h7-10H,2-6H2,1H3,(H,24,25)

Upstream product

• 103175-73-1 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(2-oxopropyl)-1-piperazinyl]-quinoline-3-carboxylic acid 
• 103258-03-3 1-ethyl-6-fluoro-1,4-dihydro-7-<4-(1-methyl-2-oxopropyl)-1-piperazinyl>-4-oxoquinoline-3-carboxylic acid 
• 110-85-0 piperazine 
• 70032-25-6 6,7-difluoro-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 70458-96-7 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid 
• 1616780-98-3 C₂₄H₂₁F₂N₅O₃S 
• 1616781-12-4 1-ethyl-6-fluoro-7-(4-(3-(6-fluorobenzo[d]thiazol-2-yl)-4-oxothiazolidin-2-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1616781-15-7 C₂₇H₂₃FN₆O₄S₂ 
• 1616781-01-1 C₂₅H₂₁FN₆O₃S 

Relevant articles and documents

Studies on Prodrugs. 10. Possible Mechanism of N-Dealkylation of N-Masked Norfloxacins Having Several Active Methylene Groups

As a prodrug approach to norfloxacin (NFLX, 2), we have prepared several N-masked NFLXs (1a-f) and studied the cleavage mechanism of the C-N bond of N-masked NFLXs utilizing the following experiments: (1) the oxidation of N-masked NFLXs (1a-f) with m-chloroperbenzoic acid (MCPBA) and their subsequent cleavage to 2 in chloroform at room temperature or at 50 deg C; (2) the liberation of NFLX from N-masked NFLXs after oral administration in mice.It was found that the chemical oxidative dealkylation of N-masked NFLXs proceeded when anion-stabilizing groups (e.g., CN, COR, COOR) are present on the α carbon of the nitrogen atom.In in vivo experiments, N-masked NFLXs having acidic hydrogens on the α carbon to the nitrogen atom also liberated NFLX (2) after oral administration.